Inactive Instrument

Mylan N.V. Stock Nasdaq

Equities

MYL

NL0011031208

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 15.19B 20.77B Sales 2025 * 14.95B 20.44B Capitalization 14.03B 19.18B
Net income 2024 * 1.86B 2.54B Net income 2025 * 932M 1.27B EV / Sales 2024 * 1.81 x
Net Debt 2024 * 13.4B 18.32B Net Debt 2025 * 11.55B 15.8B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
8.52 x
P/E ratio 2025 *
14.1 x
Employees -
Yield 2024 *
4.26%
Yield 2025 *
4.43%
Free-Float 97.9%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 22-12-28
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 20-11-15
Members of the board TitleAgeSince
Chairman 56 20-11-15
Director/Board Member 68 20-11-15
Director/Board Member 66 20-11-15
More insiders
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW